MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT
REGISTRATION IN COLOMBIA FOR VITAFLOW LIBERTY™

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that on August 3, 2022, our independently-developed second-generation transcatheter aortic valve implantation ("**TAVI**") product, the VitaFlow Liberty™ transcatheter aortic valve implantation system ("**VitaFlow Liberty™**"), and our first-generation tip-preshaped super stiff guidewire Angelguide® ("**Angelguide®**"), were successfully registered in Colombia. This is the second country in Latin America that our second-generation TAVI product has entered following Argentina providing a motorized retrievable delivery system, demonstrating the further expansion of our global influence.

As our independently-developed second-generation TAVI product, VitaFlow Liberty™ not only inherits the advantages of the VitaFlow® transcatheter aortic valve implantation system ("**VitaFlow®**") in valve design, but also achieves a breakthrough upgrade of the delivery system. It has a unique and innovative double helix structure that guarantees fast, stable and precise deployment and retrieval, and also provides optimized pass performance and 360-degree bending of the valve segment. Our guidewire product Angelguide®, which was registered together with VitaFlow Liberty™ in Colombia, features high guidewire rail support and smooth transition that can help to reduce the risks of vascular damage and enhance the accuracy of deployment.

Previously, VitaFlow Liberty™ was approved by the National Medical Products Administration of the People's Republic of China in August 2021, and received approval for registration in Argentina and submitted the registration application of the CE Mark in December 2021. We are also continuing to work on the registration of VitaFlow Liberty™ in various emerging market countries.

We believe that the registration of VitaFlow Liberty™ in Colombia marks another solid step forward on our international roadmap, and also lays a sound foundation for our structural heart disease products to enter more potential overseas markets. We will continue to enhance the promotion of our TAVI products in Latin America leveraging the global reputation of MicroPort® brand and the existing sales network of MicroPort® Group and accelerate the launch of innovative products with international competitiveness, so as to continuously benefit patients with structural heart diseases around the world with trustworthy and universal access to state-of-the-art total solutions.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, August 8, 2022

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.